
Works on desire, not blood flow
Bremelanotide acts on melanocortin receptors in the brain that are involved in sexual desire, a different pathway from blood-flow medications.









The people pictured are models, not patients.
RxSexual Health
Bremelanotide, a different mechanism from ED medicines.
40,000+ products sold · LegitScript certified
Compounded bremelanotide, also called PT-141, reviewed by a licensed provider. Vyleesi is the FDA-approved bremelanotide product for a specific form of low sexual desire in premenopausal women; this listing is for a compounded preparation.
Pause, change, or cancel anytime from your account.
This medication is prepared by a licensed compounding pharmacy. Compounded medications are not reviewed by the FDA for safety or effectiveness and are dispensed only after a licensed provider determines they are appropriate for you.
How Would You Like To Pay?
Choose Your Plan
Or pay with
$170 billed today, then every month until canceled.
Not prescribed? Full refund.
After checkout you complete a short medical review in your member portal, and a US-licensed provider reviews it before your PT-141 ships.
Full refund if not prescribed Free, discreet shipping Cancel anytime
Order today and here is what happens next
Common questions

Evenings together
The people pictured are models, not patients.

Bremelanotide acts on melanocortin receptors in the brain that are involved in sexual desire, a different pathway from blood-flow medications.

Vyleesi is FDA approved for premenopausal women with acquired, generalized HSDD. This listing is for compounded bremelanotide, a different preparation without that product approval.

You give a small subcutaneous injection about 45 minutes before intimacy, not on a daily schedule.

Your provider reviews other medicines and medical conditions before deciding whether a prescription is appropriate.
How we compare
Understand your treatment
PT-141, also known as bremelanotide, acts on melanocortin receptors. That is a different mechanism from the PDE5 pathway used by sildenafil and tadalafil. Desire and the physical response are related parts of sexual wellbeing, but they are not the same endpoint. Understanding the ingredient helps you compare a desire-focused discussion with an erection-focused one, and an injectable product with a nasal blend.
A closer look
Desire has a different pathway.
Make a more informed choice
The ingredient class and route are the important differences. PT-141 is a melanocortin-receptor agonist. Tadalafil and sildenafil are PDE5 inhibitors. This page is the injectable PT-141 option.

Choose your treatment options and complete secure checkout. Then complete the online health intake.
A licensed physician (MD) reviews your completed intake and decides whether bremelanotide is right for you.
If approved, a US-licensed pharmacy prepares your injection and ships it discreetly in 3 to 5 days.
Message your care team any time. Your provider can adjust timing or dose based on how you respond and tolerate it.
Bremelanotide activates melanocortin receptors. Its mechanism differs from PDE5 medicines such as sildenafil, which act on blood flow. A different mechanism does not establish that combining treatments is beneficial or appropriate for a particular person.
You inject a small dose
A subcutaneous injection is given about 45 minutes before intimacy.
It activates melanocortin receptors
Bremelanotide stimulates melanocortin receptors in the hypothalamus, part of the brain's desire circuitry.
Desire signaling is engaged
This pathway is separate from the blood-flow mechanism that PDE5 medicines use.
Bremelanotide engages the brain pathways tied to sexual desire. It does not act on blood flow, so it works differently from ED pills.
Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its evidence base comes from the two randomized, placebo-controlled RECONNECT phase 3 trials. The trials studied the approved product and population, not this compounded formulation.
+0.35
Across the two RECONNECT phase 3 trials, bremelanotide increased the FSFI sexual-desire score versus placebo in premenopausal women with HSDD, an integrated change of 0.35 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
Less distress
In the same trials, bremelanotide reduced desire-related distress on the FSDS-DAO versus placebo, an integrated change of 0.33 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
52 weeks
In a 52-week open-label extension, no new safety signals were seen. The most common side effect was nausea, reported by about 40 percent of participants.
Simon et al., Obstet Gynecol 2019
Two different mechanisms
| PT-141 (bremelanotide) | PDE5 pills like sildenafil | |
|---|---|---|
| How it works | Acts on desire pathways in the brain | Increases blood flow in the body |
| What it targets | Low desire and arousal | Physical erection and blood flow |
| Format | Subcutaneous injection | Oral tablet |
| When you use it | About 45 minutes before | About 30 to 60 minutes before |
| Regulatory status | This preparation is compounded; Vyleesi has a separate product approval | FDA-approved for erectile dysfunction |
| Combination evidence | A different mechanism does not establish combination benefit | Requires evaluation of the specific medicines and patient |
Your provider reviews your symptoms, medications, blood pressure, and medical history before deciding whether to prescribe. The RECONNECT studies evaluated a defined bremelanotide product in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Those findings do not establish equivalent outcomes for this compounded preparation or for other populations.
About 45 minutes before
Give a small subcutaneous injection roughly 45 minutes before intimacy.
45 to 90 minutes
Effects on desire typically begin within this window after the injection.
Up to a few hours
Effects can last for a few hours. Do not use more than one dose in 24 hours.
After a few tries
Your provider adjusts timing or dose based on how you respond and how well you tolerate it.
The approved Vyleesi label identifies nausea, flushing, headache, injection-site reactions, increased blood pressure, and focal hyperpigmentation among relevant risks. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. The provider must evaluate the risks of the prescribed formulation and give its specific instructions.
Not for use during pregnancy or when trying to conceive. Not for people with uncontrolled high blood pressure or known cardiovascular disease. Do not use more than one dose in 24 hours or more than eight per month. Tell your provider about all heart and blood pressure conditions. This compounded use is off-label except in premenopausal women with HSDD.

An independent US-licensed clinician reviews every request. If they decide the treatment is not right for you, you get a full refund for the medication.
Prescriptions are filled by a US-licensed pharmacy and shipped free, in discreet packaging, on every plan.
LegitScript-certified · Cert 50087439
Compounded medications are prepared by a US-licensed pharmacy and are not reviewed by the FDA for safety or effectiveness. Products are dispensed only after a licensed provider determines they are appropriate. Information here is educational and is not a substitute for medical advice.